Pharmacokinetic and pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcome

References

• Abou-Khalil B. (2008). Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat 4:507–23.
   PubMedGoogle Scholar
• Benedetti MS, Coupez R, Whomsley R, et al. (2004). Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog. Xenobiotica 34:281–300.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Edrich P, Van Vleymen B, et al. (2003). Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 53:57–64.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Falter U. (2000). Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41:1276–83.
   PubMed Web of Science ®Google Scholar
• Berković SF, Knowlton RC, Leroy RF, et al. (2007). Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69:1751–60.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Perucca E, Ryvlin P, et al. (2007). Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68:402–8.
   PubMed Web of Science ®Google Scholar
• Cereghino JJ, Biton V, Abou-Khalil B, et al. (2000). Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55:236–42.
   PubMed Web of Science ®Google Scholar
• Chhun S, Jullien V, Rey E, et al. (2009). Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Epilepsia 50:1150–7.
   PubMed Web of Science ®Google Scholar
• Crepeau AZ, Treiman DM. (2010). Levetiracetam: a comprehensive review. Expert Rev Neurother 10:159–71.
   PubMed Web of Science ®Google Scholar
• Hernández-Mitre MP, Medellín-Garibay SE, Rodríguez-Leyva I, et al. (2020). Population pharmacokinetics and dosing recommendations of levetiracetam in adult and elderly patients with epilepsy. J Pharm Sci. doi:10.1016/j.xphs.2020.02.018. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ito S, Yano I, Hashi S, et al. (2016). Population pharmacokinetic modeling of levetiracetam in pediatric and adult patients with epilepsy by using routinely monitored data. Ther Drug Monit 38:371–8.
   PubMed Web of Science ®Google Scholar
• Jovanović M, Sokić D, Grabnar I, et al. (2013). Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. Eur J Pharm Sci 50:282–9.
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Matagne A, Leclercq K, et al. (2008). SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54:715–20.
   PubMed Web of Science ®Google Scholar
• Keppra SmPC. (2016). Keppra® UCB Pharma Limited, summary of product characteristics. Brussels, Belgium: Keppra SmPC. UCB Pharma S.A.
   Google Scholar
• Kim MJ, Yum MS1, Yeh HR, et al. (2018). Pharmacokinetic and pharmacodynamic evaluation of intravenous levetiracetam in children with epilepsy. J Clin Pharmacol 58:1586–96.
   PubMed Web of Science ®Google Scholar
• Krasowski MD. (2010). Therapeutic drug monitoring of the newer anti-epilepsy medications. Pharmaceuticals 3:1909–35.
   Google Scholar
• Kumar A, Kadian R. (2020). Levetiracetam. Treasure Island (FL): StatPearls Publishing.
   Google Scholar
• Lee JW, Dworetzky B. (2010). Rational polytherapy with antiepileptic drugs. Pharmaceuticals (Basel) 3:2362–79.
   PubMedGoogle Scholar
• Lynch BA, Lambeng N, Nocka K, et al. (2004). The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101:9861–6.
   PubMed Web of Science ®Google Scholar
• Monolix Userguide. (2019). Categorical data model. Available from: http://monolix.lixoft.com/data-and-models/categoricaldata/ [last accessed 2 Oct 2019].
   Google Scholar
• Nakken KO, Eriksson AS, Lossius R, Johannessen SI. (2003). A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. Seizure 12:42–6.
   PubMed Web of Science ®Google Scholar
• Noachtar S, Andermann E, Meyvisch P, et al. (2008). N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70:607–16.
   PubMed Web of Science ®Google Scholar
• Park KM, Kim SE, Lee B. (2019). Antiepileptic drug therapy in patients with drug-resistant epilepsy. J Epilepsy Res 9:14–26.
   PubMedGoogle Scholar
• Pasala S, Carmody JB. (2017). How to use serum creatinine, cystatin C and GFR. Arch Dis Child Educ Pract Ed 102:37–43.
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BF, et al. (2008). Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies. Epilepsia 49:1239–76.
   PubMed Web of Science ®Google Scholar
• Pigeolet E, Jacqmin P, Sargentini-Maier ML, Stockis A. (2007). Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clin Pharmacokinet 46:503–12.
   PubMed Web of Science ®Google Scholar
• Plan EL. (2014). Modeling and simulation of count data. CPT Pharmacometr Syst Pharmacol 3:e129.
   PubMedGoogle Scholar
• Rhee SJ, Shin JW, Lee S, et al. (2017). Population pharmacokinetics and dose–response relationship of levetiracetam in adult patients with epilepsy. Epilepsy Res 132:8–14.
   PubMed Web of Science ®Google Scholar
• Schoemaker R, Wade JR, Stockis A. (2016). Brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial-onset seizures. J Clin Pharmacol 56:1591–602.
   PubMed Web of Science ®Google Scholar
• Shorvon SD, Löwenthal A, Janz D, et al. (2000). Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 41:1179–86.
   PubMed Web of Science ®Google Scholar
• Spencer DD, Jacobi J, Juenke JM, et al. (2011). Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. Pharmacotherapy 31:934–41.
   PubMed Web of Science ®Google Scholar
• Strolin Benedetti M, Whomsley R, Nicolas JM, et al. (2003). Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol 59:621–30.
   PubMed Web of Science ®Google Scholar
• Toublanc N, Lacroix BD, Yamamoto J. (2014). Development of an integrated population pharmacokinetic model for oral levetiracetam in populations of various ages and ethnicities. Drug Metab Pharmacokinet 29:61–8.
   PubMed Web of Science ®Google Scholar
• Toublanc N, Sargentini-Maier ML, Lacroix B, et al. (2008). Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. Clin Pharmacokinet 47:333–41.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Jiang J, Li XM, et al. (2007). Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. Br J Clin Pharmacol 63:614–7.
   PubMed Web of Science ®Google Scholar